Trials / Terminated
TerminatedNCT03483883
Avelumab/Gemcitabine in Sarcomatoid RCC
A Phase I/IB Study of Avelumab in Combination With Gemcitabine for Advanced Renal Cell Carcinoma With Sarcomatoid Differentiation
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab | Avelumab IV 10 mg/kg every 2 weeks |
| DRUG | Gemcitabine | Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks |
Timeline
- Start date
- 2018-03-19
- Primary completion
- 2020-07-22
- Completion
- 2021-02-10
- First posted
- 2018-03-30
- Last updated
- 2022-08-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03483883. Inclusion in this directory is not an endorsement.